The good value of the AUC and DCA performance suggests that Treg cells combined with HLA-DR + CD4 + T cells and Naive CD4 + T cells can be used to predict CR in patients with LC who receive PD-1/PD-L1 inhibitor therapy. This evidence concerns the gene CD4 and laryngotracheoesophageal cleft.